Stock Track | West Pharmaceutical Soars 9.33% in Pre-Market on Strong Q1 Results and Raised Guidance

Stock Track

Apr 23

West Pharmaceutical Services' stock surged 9.33% in pre-market trading following the release of its first-quarter 2026 financial results.

The injectable solutions provider reported quarterly adjusted earnings per share of $2.13, significantly beating the consensus estimate of $1.68. Net sales for the quarter reached $844.9 million, also surpassing analyst expectations of $780 million. The company attributed this strong performance to organic growth in High-Value Product Components, increased sales of self-injection device platforms, and a successful production ramp-up in Europe.

Adding to investor optimism, West Pharmaceutical raised its full-year 2026 guidance. The company now expects adjusted EPS in the range of $8.40 to $8.75, up from its prior outlook of $7.85 to $8.20 and above the consensus estimate of $8.01. Full-year revenue guidance was also increased to $3.30 billion to $3.35 billion, compared to the previous range of $3.22 billion to $3.28 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1124395468"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124395468\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124395468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124395468","market":"hk","top_or_hot":-1,"title":"Stock Track | West Pharmaceutical Soars 9.33% in Pre-Market on Strong Q1 Results and Raised Guidance","media":"Stock Track","content":"<p>West Pharmaceutical Services' stock surged 9.33% in pre-market trading following the release of its first-quarter 2026 financial results.</p><p>The injectable solutions provider reported quarterly adjusted earnings per share of $2.13, significantly beating the consensus estimate of $1.68. Net sales for the quarter reached $844.9 million, also surpassing analyst expectations of $780 million. The company attributed this strong performance to organic growth in High-Value Product Components, increased sales of self-injection device platforms, and a successful production ramp-up in Europe.</p><p>Adding to investor optimism, West Pharmaceutical raised its full-year 2026 guidance. The company now expects adjusted EPS in the range of $8.40 to $8.75, up from its prior outlook of $7.85 to $8.20 and above the consensus estimate of $8.01. Full-year revenue guidance was also increased to $3.30 billion to $3.35 billion, compared to the previous range of $3.22 billion to $3.28 billion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | West Pharmaceutical Soars 9.33% in Pre-Market on Strong Q1 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | West Pharmaceutical Soars 9.33% in Pre-Market on Strong Q1 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-23 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>West Pharmaceutical Services' stock surged 9.33% in pre-market trading following the release of its first-quarter 2026 financial results.</p><p>The injectable solutions provider reported quarterly adjusted earnings per share of $2.13, significantly beating the consensus estimate of $1.68. Net sales for the quarter reached $844.9 million, also surpassing analyst expectations of $780 million. The company attributed this strong performance to organic growth in High-Value Product Components, increased sales of self-injection device platforms, and a successful production ramp-up in Europe.</p><p>Adding to investor optimism, West Pharmaceutical raised its full-year 2026 guidance. The company now expects adjusted EPS in the range of $8.40 to $8.75, up from its prior outlook of $7.85 to $8.20 and above the consensus estimate of $8.01. Full-year revenue guidance was also increased to $3.30 billion to $3.35 billion, compared to the previous range of $3.22 billion to $3.28 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WST","symbol_name":"West Pharmaceutical Services Inc","start_time":0,"source_url":"","article_id":"1124395468","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124395468","pubTimestamp":1776942160,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"West Pharmaceutical Services' stock surged 9.33% in pre-market trading following the release of its first-quarter 2026 financial results.The injectable solutions provider reported quarterly adjusted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WST":"West Pharmaceutical Services Inc"},"translate_title":"个股赛道|西部药业盘前大涨9.33%Q1业绩强劲并上调指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WST":1},"content_text":"West Pharmaceutical Services' stock surged 9.33% in pre-market trading following the release of its first-quarter 2026 financial results.The injectable solutions provider reported quarterly adjusted earnings per share of $2.13, significantly beating the consensus estimate of $1.68. Net sales for the quarter reached $844.9 million, also surpassing analyst expectations of $780 million. The company attributed this strong performance to organic growth in High-Value Product Components, increased sales of self-injection device platforms, and a successful production ramp-up in Europe.Adding to investor optimism, West Pharmaceutical raised its full-year 2026 guidance. The company now expects adjusted EPS in the range of $8.40 to $8.75, up from its prior outlook of $7.85 to $8.20 and above the consensus estimate of $8.01. Full-year revenue guidance was also increased to $3.30 billion to $3.35 billion, compared to the previous range of $3.22 billion to $3.28 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}